ASYMMETRYBETA
Loading RPRX...
Royalty Pharma PLCRPRXAs of 31 July 2026
Trailing (TTM)
Price to earnings·
Price to sales·
Price to book·
Price to op. cash flow·
Price to free cash flow·
Forward P/S (NTM)
Forward P/S (Y1)·
Forward P/S (Y2)·
Forward P/S (Y3)·
Forward P/S (Y4)·
Forward P/S (Y5)·
Forward P/E (NTM)
Forward P/E (Y1)·
Forward P/E (Y2)·
Forward P/E (Y3)·
Forward P/E (Y4)·
Forward P/E (Y5)·
Forward EV/EBIT (NTM)
Forward EV/EBIT (Y1)·
Forward EV/EBIT (Y2)·
Forward EV/EBIT (Y3)·
Forward EV/EBIT (Y4)·
Forward EV/EBIT (Y5)·
−300−1500+150+300
−15
PositiveNegative
Equilibrium
Valuation+62
CheapExpensive
Emotion+3
FearGreed
Fundamentals+81
WeakStrong
Valuation

Is Royalty Pharma PLC undervalued or overvalued?

Where Royalty Pharma PLC (RPRX) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.

Royalty Pharma PLCRPRXLast 5 years
V—E—F—A—
——
RPRX priceasymmetryquant.com
A Asymmetry—
V Valuation—
E Emotion—
F Fundamentals—